Epidemic meningitis, meningococcaemia, and Neisseria meningitidis, The Lancet, vol.369, issue.9580, pp.2196-2210, 2007. ,
DOI : 10.1016/S0140-6736(07)61016-2
Neisseria meningitidis group B correlates of protection and assay standardization???International Meeting Report Emory University, Atlanta, Georgia, United States, 16???17 March 2005, Vaccine, vol.24, issue.24, pp.5093-5107, 2006. ,
DOI : 10.1016/j.vaccine.2006.03.091
An IgG monoclonal antibody to group B meningococci cross reacts with developmentally regulated polysialic acid units of glycoproteins in neural and extraneural tissues, J Immunol, vol.138, pp.4402-4407, 1987. ,
ANTIGENIC SIMILARITIES BETWEEN BRAIN COMPONENTS AND BACTERIA CAUSING MENINGITIS Implications for Vaccine Development and Pathogenesis, The Lancet, vol.322, issue.8346, pp.355-357, 1983. ,
DOI : 10.1016/S0140-6736(83)90340-9
MeNZB?: a safe and highly immunogenic tailor-made vaccine against the New Zealand serogroup B disease epidemic strain, Vaccine, vol.23, issue.17-18, pp.2191-2196, 2005. ,
DOI : 10.1016/j.vaccine.2005.01.063
Functional and specific antibody responces in adult volunteers in New Zealand who were given one of two different meningococcal serogroup B outer membrane vesicle vaccines. Clin Vaccine Immunol, pp.830-838, 2007. ,
Using Three Variants of the Lipoprotein GNA1870, The Journal of Experimental Medicine, vol.63, issue.6, pp.789-799, 2003. ,
DOI : 10.1128/IAI.70.8.4447-4461.2002
Neisseria meningitidis GNA2132, a heparin-binding protein that induces protective immunity in humans, Proceedings of the National Academy of Sciences, vol.107, issue.8, pp.3770-3775, 2010. ,
DOI : 10.1073/pnas.0915162107
Immunogenicity and Safety of a Multicomponent Meningococcal Serogroup B Vaccine and a Quadrivalent Meningococcal CRM197 Conjugate Vaccine against Serogroups A, C, W-135, and Y in Adults Who Are at Increased Risk for Occupational Exposure to Meningococcal Isolates, Clinical and Vaccine Immunology, vol.18, issue.3, pp.483-486, 2011. ,
DOI : 10.1128/CVI.00304-10
Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England, The Lancet, vol.357, issue.9251, pp.195-196, 2001. ,
DOI : 10.1016/S0140-6736(00)03594-7
Meningococcal polysaccharide???protein conjugate vaccines, The Lancet Infectious Diseases, vol.5, issue.1, pp.21-30, 2005. ,
DOI : 10.1016/S1473-3099(04)01251-4
Serological Basis for Use of Meningococcal Serogroup C Conjugate Vaccines in the United Kingdom: Reevaluation of Correlates of Protection, Infection and Immunity, vol.69, issue.3, pp.1568-1573, 2001. ,
DOI : 10.1128/IAI.69.3.1568-1573.2001
Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from post licensure surveillance in England, Clin Diagn Lab Immunol, vol.10, issue.5, pp.780-786, 2003. ,
Investigation of serum bactericidal activity in childhood and adolescence 3???6 years after vaccination with a single dose of serogroup C meningococcal conjugate vaccine, Vaccine, vol.27, issue.33, pp.274408-4411, 2009. ,
DOI : 10.1016/j.vaccine.2009.05.047
Genetics shifts of Neisseria meningitidis serogroup B antigens and the quest for a broadly cross-protective vaccine, Expert Rev Vaccines, vol.2010, issue.910, pp.1203-1217 ,
Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease, Vaccine, vol.27, issue.2, pp.112-116, 2009. ,
DOI : 10.1016/j.vaccine.2009.04.065
Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines, Proceedings of the National Academy of Sciences, vol.107, issue.45, pp.19490-19495, 2010. ,
DOI : 10.1073/pnas.1013758107
Understanding the Immune Responses to the Meningococcal Strain-Specific Vaccine MeNZB Measured in Studies of Infants, Clinical and Vaccine Immunology, vol.13, issue.7, pp.797-801, 2006. ,
DOI : 10.1128/CVI.00038-06
Virulence Factors of Gram-Negative Bacteria in Sepsis with a Focus on <i>Neisseria meningitidis</i>, Contrib Microbiol, vol.17, pp.31-47, 2011. ,
DOI : 10.1159/000324008
Inter-laboratory standardization of the sandwich ELISA designed for MATS, a rapid, reproducible method for estimating the strain coverage of investigational vaccines, Clin Vaccine Immunol, vol.2012, issue.1910, pp.1609-1617 ,
Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment, The Lancet Infectious Diseases, vol.13, issue.5, pp.416-425 ,
DOI : 10.1016/S1473-3099(13)70006-9
Diversity of Canadian meningococcal serogroup B isolates and estimated coverage by an investigational meningococcal serogroup B vaccine (4CMenB), Vaccine, vol.32, issue.1, 2013. ,
DOI : 10.1016/j.vaccine.2013.03.063
Surveillance of Bacterial invasive Diseases in Europe, 2008. ,
Analysis of PorA variable region 3 in meningococci: implications for vaccine policy?, Vaccine, vol.21, issue.19-20, pp.19-202468, 2003. ,
DOI : 10.1016/S0264-410X(03)00033-1
Genosubtyping by sequencing group A, B and C meningococci; a tool for epidemiological studies of epidemics, clusters and sporadic cases, APMIS, vol.44, issue.Pt 1, pp.509-516, 2000. ,
DOI : 10.1034/j.1600-0463.2000.01087-8509.x
The porA gene in serogroup A meningococci: evolutionary stability and mechanism of genetic variation, Molecular Microbiology, vol.167, issue.2, pp.253-265, 1994. ,
DOI : 10.1084/jem.175.1.227
NadA Diversity and Carriage in Neisseria meningitidis, Infection and Immunity, vol.72, issue.7, pp.4217-4223, 2004. ,
DOI : 10.1128/IAI.72.7.4217-4223.2004
Sequence constancies and variations in genes encoding three new meningococcal vaccine candidate antigens, Vaccine, vol.24, issue.12, pp.2161-2168, 2006. ,
DOI : 10.1016/j.vaccine.2005.11.006
Characterization of fHbp, nhba (gna2132), nadA, porA, and Sequence Type in Group B Meningococcal Case Isolates Collected in England and Wales during January 2008 and Potential Coverage of an Investigational Group B Meningococcal Vaccine, Clinical and Vaccine Immunology, vol.17, issue.6, pp.919-929, 2008. ,
DOI : 10.1128/CVI.00027-10
Distribution and genetic variability of three vaccine components in a panel of strains representative of the diversity of serogroup B meningococcus, Vaccine, vol.27, issue.21, pp.2794-2803, 2009. ,
DOI : 10.1016/j.vaccine.2009.02.098
The VR2 Epitope on the PorA P1.7-2,4 Protein Is the Major Target for the Immune Response Elicited by the Strain-Specific Group B Meningococcal Vaccine MeNZB, Clinical and Vaccine Immunology, vol.13, issue.4, pp.486-491, 2006. ,
DOI : 10.1128/CVI.13.4.486-491.2006
Distribution of Serogroups and Genotypes among Disease-Associated and Carried Isolates of Neisseria meningitidis from the Czech Republic, Greece, and Norway, Journal of Clinical Microbiology, vol.42, issue.11, pp.425146-5153, 2004. ,
DOI : 10.1128/JCM.42.11.5146-5153.2004
Variable-Number Tandem Repeat Analysis of Meningococcal Isolates Belonging to the Sequence Type 162 Complex, Journal of Clinical Microbiology, vol.43, issue.9, pp.4865-4867, 2005. ,
DOI : 10.1128/JCM.43.9.4865-4867.2005
Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage, Vaccine, vol.31, issue.43, pp.314968-4974 ,
DOI : 10.1016/j.vaccine.2013.08.006
Transcriptional Regulation of the nadA Gene in Neisseria meningitidis Impacts the Prediction of Coverage of a Multicomponent Meningococcal Serogroup B Vaccine, Infection and Immunity, vol.81, issue.2, pp.560-569, 2013. ,
DOI : 10.1128/IAI.01085-12